Related Experiment Videos
Blood stem cells as therapy for severe lupus
Gabor G Illei1, Steven Z Pavletic
1National Institute of Dental and Craniofacial Research, Sjögren's Syndrome Clinic, 9000 Rockville Pike, Bethesda, MD 20892-1190, USA. illeig@mail.nih.gov
Expert Opinion on Biological Therapy
|August 27, 2005
Summary
High-dose immunosuppression with autologous stem cell therapy shows promise for long-term systemic lupus erythematosus (SLE) response, despite short-term risks. Further research into allogeneic transplantation and immune reconstitution is crucial for potential cures.
Area of Science:
- Immunology
- Hematology
- Rheumatology
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with limited treatment options for severe cases.
- High-dose immunosuppression followed by autologous hematopoietic stem cell therapy (aHSCT) offers potential for durable responses in refractory SLE.
- While aHSCT has shown significant clinical responses, its long-term efficacy and curative potential remain under investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of hematopoietic stem cell transplantation (HSCT) in patients with severe systemic lupus erythematosus (SLE).
- To explore the potential for long-term and durable responses, and possibly cure, in SLE patients undergoing HSCT.
- To highlight the importance of specialized protocols and research into immune reconstitution for HSCT in SLE.
Main Methods:
- Review of existing studies on autologous and allogeneic hematopoietic stem cell transplantation for systemic lupus erythematosus.
- Analysis of clinical response rates, durability, and procedure-related mortality in HSCT for SLE.
- Emphasis on the need for innovative, carefully planned protocols involving specialized teams.
Main Results:
- Autologous HSCT induced major clinical responses in approximately 65% of SLE patients who failed standard therapies.
- Durable responses lasting several years have been observed in some patients, but curative potential is still unknown.
- Procedure-related mortality has decreased from up to 12% in earlier studies to less than 5% in recent large-scale studies.
Conclusions:
- Autologous HSCT is a promising treatment for severe SLE, offering significant clinical responses and potential for long-term remission.
- Allogeneic HSCT from HLA-matched donors presents a strong possibility for cure, with newer, safer transplantation regimens becoming available.
- Optimal therapeutic and scientific outcomes necessitate innovative protocols, specialized multidisciplinary teams, and studies on immune reconstitution to understand HSCT mechanisms in SLE.